Victoria Wang

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial”.

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood(2022)10.1182/blood.2021014960

N/A

5.5DataRank · unranked

240 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +17 more

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Blood Advances(2025)10.1182/bloodadvances.2024013474

N/A

0.292DataRank · unranked

6 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +16 more

Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0145

N/A

0DataRank · unranked

193 citations

Sonja Bendig, Zhaohui Gu, Xiaolong Chen, Petri Pölönen, Xiaotu Ma +47 more

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood(2021)10.1182/blood.2020010146

N/A

0DataRank · unranked

35 citations

Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta +17 more

Inference in response‐adaptive clinical trials when the enrolled population varies over time

Biometrics(2021)10.1111/biom.13582

N/A

0DataRank · unranked

3 citations

Steffen Ventz, Victoria Wang, Lorenzo Trippa, Massimiliano Russo

Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.162

N/A

0DataRank · unranked

18 citations

Victoria Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den, Gerhardt Attard +10 more

Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.146

N/A

0DataRank · unranked

0 citations

Victoria Wang, Brett T. Marck, Alvin M. Matsumoto, Christopher J. Sweeney, Elahe A. Mostaghel

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Blood(2023)10.1182/blood.2023020554

N/A

0DataRank · unranked

21 citations

Victoria Wang, Tait D. Shanafelt, Connie Lesnick, Nikolaos Ioannou, Giulia De Rossi +7 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer

Endocrine Related Cancer(2024)10.1530/erc-24-0140

N/A

0DataRank · unranked

0 citations

Victoria Wang, Brett T. Marck, Nima Sharifi, Alvin M. Matsumoto, Christopher J. Sweeney +1 more

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

JCO Precision Oncology(2024)10.1200/po-24-00514

N/A

0DataRank · unranked

0 citations

Zihe Song, Andrew Poklepovic, Eric A. Collisson, James A. Zwiebel, Robert J. Gray +14 more

Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.145

N/A

0DataRank · unranked

0 citations

Victoria Wang, Ole‐Petter R. Hamnvik, Yee Ming Cheung, Xiao X. Wei, Praful Ravi +3 more

Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.171

N/A

0DataRank · unranked

1 citations

Victoria Wang, Hidemi S. Yamamoto, Anis Hamid, Charles G. Drake, Michael A. Carducci +4 more